BRPI0915977A2 - imidazol carboxamidas - Google Patents

imidazol carboxamidas

Info

Publication number
BRPI0915977A2
BRPI0915977A2 BRPI0915977A BRPI0915977A BRPI0915977A2 BR PI0915977 A2 BRPI0915977 A2 BR PI0915977A2 BR PI0915977 A BRPI0915977 A BR PI0915977A BR PI0915977 A BRPI0915977 A BR PI0915977A BR PI0915977 A2 BRPI0915977 A2 BR PI0915977A2
Authority
BR
Brazil
Prior art keywords
imidazole carboxamides
carboxamides
imidazole
Prior art date
Application number
BRPI0915977A
Other languages
English (en)
Portuguese (pt)
Inventor
Khilevich Albert
Liu Bin
Ray Mayhugh Daniel
Zhang Deyi
Michael Schkeryantz Jeffrey
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0915977A2 publication Critical patent/BRPI0915977A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91Nitro radicals
    • C07D233/92Nitro radicals attached in position 4 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
BRPI0915977A 2008-07-18 2009-07-14 imidazol carboxamidas BRPI0915977A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8177408P 2008-07-18 2008-07-18
PCT/US2009/050440 WO2010009062A1 (en) 2008-07-18 2009-07-14 Imidazole carboxamides

Publications (1)

Publication Number Publication Date
BRPI0915977A2 true BRPI0915977A2 (pt) 2018-10-30

Family

ID=41128155

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915977A BRPI0915977A2 (pt) 2008-07-18 2009-07-14 imidazol carboxamidas

Country Status (19)

Country Link
US (1) US7754742B2 (enExample)
EP (1) EP2318375B1 (enExample)
JP (1) JP5379227B2 (enExample)
KR (1) KR101287713B1 (enExample)
CN (1) CN102099344B (enExample)
AR (1) AR074631A1 (enExample)
BR (1) BRPI0915977A2 (enExample)
CA (1) CA2731215C (enExample)
CY (1) CY1113315T1 (enExample)
DK (1) DK2318375T3 (enExample)
EA (1) EA018434B1 (enExample)
ES (1) ES2393243T3 (enExample)
HR (1) HRP20120830T1 (enExample)
MX (1) MX2011000611A (enExample)
PL (1) PL2318375T3 (enExample)
PT (1) PT2318375E (enExample)
SI (1) SI2318375T1 (enExample)
TW (1) TW201006801A (enExample)
WO (1) WO2010009062A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
KR20100080597A (ko) 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 1,3-이치환된-4-페닐-1h-피리딘-2-온
CA2696948C (en) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2681196B1 (en) 2011-03-04 2015-09-09 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
TN2017000342A1 (en) 2015-02-03 2019-01-16 Pfizer Novel cyclopropabenzofuranyl pyridopyrazinediones
CN107207449B (zh) 2015-04-23 2020-11-10 豪夫迈·罗氏有限公司 用于治疗精神障碍的四唑衍生物
CN104788694B (zh) * 2015-04-29 2018-06-08 江苏亚宝绝缘材料股份有限公司 一种超低收缩率的聚酰亚胺薄膜
EP3359537B1 (en) 2015-10-06 2020-03-25 H. Hoffnabb-La Roche Ag Triazole derivatives
JP6905988B2 (ja) 2016-02-02 2021-07-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Eaat3阻害剤としてのピラゾール−ピリジン誘導体
CN109071451B (zh) 2016-05-27 2022-07-15 豪夫迈·罗氏有限公司 作为eaat3抑制剂的吡唑化合物
EP3526201B1 (en) 2016-10-14 2020-11-18 H. Hoffnabb-La Roche Ag Imidazole compounds as eaat3 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE7897T1 (de) 1979-09-05 1984-06-15 Glaxo Group Limited Phenol-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
US4666928A (en) 1984-08-30 1987-05-19 Merck Frosst Canada, Ind. Propylphenoxy pyridine carboxylates as leukotriene antagonists
TW204343B (enExample) 1991-05-31 1993-04-21 Sumitomo Pharmaceutics Co Ltd
US6800651B2 (en) 2000-02-03 2004-10-05 Eli Lilly And Company Potentiators of glutamate receptors
JP2006502143A (ja) 2002-08-26 2006-01-19 メルク エンド カムパニー インコーポレーテッド 向代謝型グルタミン酸受容体のアセトフェノン増強因子
WO2006014918A2 (en) * 2004-07-30 2006-02-09 Merck & Co., Inc. Heterocyclic acetophenone potentiators of metabotropic glutamate receptors
AU2005267883A1 (en) 2004-07-30 2006-02-09 Merck & Co., Inc. Indanone potentiators of metabotropic glutamate receptors
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
AU2005299797A1 (en) 2004-10-25 2006-05-04 Merck & Co., Inc. Heterocyclic indanone potentiators of metabotropic glutamate receptors
ES2333979T3 (es) * 2004-11-22 2010-03-03 Eli Lilly And Company Potenciadores de los receptores del glutamato.
CN101128435A (zh) 2004-12-27 2008-02-20 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体激动剂用于治疗神经病学及精神病学病症的吡唑酮化合物
CN101309905A (zh) 2005-08-12 2008-11-19 阿斯利康(瑞典)有限公司 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途

Also Published As

Publication number Publication date
EA201170227A1 (ru) 2011-06-30
SI2318375T1 (sl) 2012-11-30
PL2318375T3 (pl) 2013-02-28
TW201006801A (en) 2010-02-16
US7754742B2 (en) 2010-07-13
EP2318375A1 (en) 2011-05-11
CN102099344A (zh) 2011-06-15
EA018434B1 (ru) 2013-07-30
PT2318375E (pt) 2012-10-22
KR101287713B1 (ko) 2013-07-23
KR20110022676A (ko) 2011-03-07
CY1113315T1 (el) 2016-04-13
CA2731215C (en) 2013-08-27
US20100016373A1 (en) 2010-01-21
CA2731215A1 (en) 2010-01-21
JP5379227B2 (ja) 2013-12-25
CN102099344B (zh) 2013-10-30
MX2011000611A (es) 2011-03-01
AR074631A1 (es) 2011-02-02
JP2011528658A (ja) 2011-11-24
ES2393243T3 (es) 2012-12-19
DK2318375T3 (da) 2012-10-08
HRP20120830T1 (hr) 2012-11-30
WO2010009062A1 (en) 2010-01-21
EP2318375B1 (en) 2012-09-19
AU2009271105A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
DK2318375T3 (da) Imidazolcarboxamider
BR112012010502A2 (pt) derivados de benzimidazol-imidazol
EP2303378A4 (en) INTERFACE
PT2813570T (pt) Resumo
BRPI0919116A2 (pt) método
EP2351549A4 (en) INTERCONNECTS
DK2308869T3 (da) Azolforbindelse
BRPI0817609A2 (pt) Derivados de imidazol
PT3045471T (pt) Resumo
BRPI0914743A2 (pt) estrutura
FI20080462A0 (fi) Einespakkaus
DK2313489T3 (da) Fremstillingsmetode
EP2351082A4 (en) METAL-INSULATOR-METAL CAPACITORS
BRPI0914274A2 (pt) plataforma
DK3421796T3 (da) Køleapparat
EP2326553A4 (en) TRIM FLAP
BRPI0818855A2 (pt) Derivados de imidazol
DK2300238T3 (da) Skyggebillede-sikkerhedstræk
BRPI0907963A2 (pt) Derivados de indazola
FI20085672A0 (fi) Säiliö
DK2379722T3 (da) Ekspressionsvektor
BRPI0916597A2 (pt) Método
DE112008004073T8 (de) Tank
FI20085899A0 (fi) Puu-Metalli-komposiittirakenne
DE112009001697A5 (de) Pumpeneinheit

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.